Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT). Tap, W. D., Gelderblom, H., Stacchiotti, S., Palmerini, E., Ferrari, S., Desai, J., Bauer, S., Blay, J., Alcindor, T., Ganjoo, K. N., Broto, J., Ryan, C. W., Shuster, D., Zhang, L., Wang, Q., Hsu, H., Lin, P. S., Tong, S., Wagner, A. J. AMER SOC CLINICAL ONCOLOGY. 2018

View details for DOI 10.1200/JCO.2018.36.15_suppl.11502

View details for Web of Science ID 000442916003585